Summit Therapeutics PLC's investigational drug candidate for Duchenne muscular dystrophy (DMD) ezutromid has reduced muscle damage in patients at the 24-week point in an ongoing Phase II trial, but the real test of the utrophin modulator's efficacy will come with the top-line results due in the third quarter of 2018.
Nonetheless, shares in Summit rose by nearly 13% to close at $13.78 on Nasdaq on Jan. 25 as investors digested the product's potential. Summit said the combination of reduced muscle...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?